Daa Pangenotypic Mavyret denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for daa pangenotypic mavyret are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Mavyret on Medical-Necessity Grounds

Aetna's medical-necessity reviews for pangenotypic direct-acting antivirals (DAAs) like Mavyret (glecaprevir/pibrentasvir) typically require documentation that your hepatitis C diagnosis, genotype, treatment history, and disease stage each satisfy criteria spelled out in Aetna's current Hepatitis C coverage policy. Denials often result from incomplete chart submission — a missing genotype report, an undocumented prior-treatment history, or a fibrosis-staging result that was not explicitly linked to the prescriber's medical-necessity letter.

## Why This Denial Is Appealable

HCV is a serious, progressive, and curable disease. Mavyret holds FDA approval for the indication your prescriber submitted. A denial that ignores documented clinical evidence is subject to reversal at both the internal and external review levels.

## Federal Appeal Framework

• ACA §2719 / ERISA §503: Non-grandfathered group and individual plans must provide a full-and-fair internal review followed by an independent external review.
• Timeline: You generally have 180 days from the denial notice to file an internal appeal. If the internal appeal is denied, you typically have 4 months from that second denial to request external review.
• Expedited option: If delay would seriously jeopardize your health, request an expedited review — a decision is generally required within 72 hours.

## The Appeal Process

1. Request Aetna's complete denial file (the Explanation of Benefits and the clinical rationale letter). 2. Obtain a copy of Aetna's current Hepatitis C DAA coverage/medical policy. 3. Have your prescriber write a detailed medical-necessity letter addressing each criterion in that policy. 4. Submit the internal appeal with the full documentation package. 5. If denied again, file for independent external review through your state's external review organization or the federal process.

## Documentation to Gather

• Diagnosis confirmation: Lab report confirming active HCV infection and the specific genotype result.
• Disease severity: Liver fibrosis or cirrhosis staging from biopsy, elastography, or validated non-invasive scoring, as reflected in the chart.
• Treatment history: Dates, regimens, outcomes, and reasons for discontinuation of any prior HCV therapy (or clear documentation of treatment-naive status).
• Comorbidities: Any conditions (e.g., renal impairment, HIV co-infection, decompensated cirrhosis) that influenced regimen selection, per the prescribing label.
• Prescriber letter: A signed letter from your hepatologist or gastroenterologist explaining why Mavyret is medically necessary for your specific case.

## Criteria-Mapping Structure

Create a two-column table. In the left column, copy each requirement verbatim from Aetna's published coverage policy and from the FDA-approved Mavyret prescribing label. In the right column, cite the exact chart fact, date, and source document that satisfies each requirement. A complete, point-by-point match is the single most effective tool for reversing a medical-necessity denial.